Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival

• Main Authors: Hind A. Alkhatabi (Author), Samir F. Zohny (Author), Mohammed Razeeth Shait Mohammed (Author), Hani Choudhry (Author), Mohd Rehan (Author), Aamir Ahmad (Author), Farid Ahmed (Author), Mohammad Imran Khan (Author)
• Format: Book
• Published: MDPI AG, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid leukemia (AML) or elderly patients non-eligible for chemotherapy. However, acquiring resistance to ven...